Why the Reva Medical share price is up 20% today

The Reva Medical Inc (ASX:RVA) share price is volatile.

| More on:
medical app, medical, healthcare, mobile

The Reva Medical Inc (ASX: RVA) share price is up 20% or 4 cents to 24 cents today after the US-based medical device hopeful yesterday reported that it has expanded into seven new European countries “with the addition of four new distribution partnerships”.

The company reports it is “focused on the development and commercialisation of bioresorbable polymer technologies for vascular applications”, with products including the Fantom Encore and “MOTIV bioresorbable vascular scaffolds for the treatment of coronary artery disease and below-the-knee peripheral artery disease.”

For the quarter ending September 30 2018 Reva posted an operating cash loss and has a market value around A$83 million according to Commsec. Reva also reports that it’s considering a US stock market listing in 2019.

It claims to have plans to become a $1 billion plus company, but for now its cash flows are negative and its share price is unsurprisingly volatile.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News